Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Language
Document Type
Year range
1.
14th International Conference on Cross-Cultural Design, CCD 2022 Held as Part of the 24th HCI International Conference, HCII 2022 ; 13313 LNCS:230-240, 2022.
Article in English | Scopus | ID: covidwho-1919665

ABSTRACT

Social media is one of the most significant sources of information in modern people’s life. Due to the large quantity of user base and public opinions, when people read a blog post, the different tendencies of comments may affect their views on the event to a certain extent. This paper, taking the COVID-19 epidemic as an example, investigated the impact of Weibo (a popular social software in China) comments on readers’ sentiments. In this paper, text mining technology was adopted to collect data including the blogs and the comments under each blog, and the NLPIR-Parser platform was used to analyze the sentiment of the comments. Finally, the conclusion that the sentiments of other comments tend to follow the sentiments of the first comments was drawn. Based on the research results, this paper also gave some enlightenment on social media management and suggestions of public opinions oversight. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.

2.
Aging-Us ; 13(7):9253-9264, 2021.
Article in English | Web of Science | ID: covidwho-1250893

ABSTRACT

This study analyzed the effect of Arbidol, a broad-spectrum antiviral compound, on the outcomes of COVID-19 patients. Records of 252 COVID-19 patients were retrospectively analyzed from February 13 to February 29, 2020 in 4 inpatient wards in the Cancer Center, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. The rate of clinical improvement was significantly greater among patients treated with Arbidol than among those who did not receive Arbidol (86.8% vs. 54.2%). In moderately and severely ill patients, the clinical improvement rates in the Arbidol group were 95.6% and 81.7%, respectively, which was significantly higher than in the no-Arbidol group (66.6% and 53.8%). Among critically ill patients, however, there was no significant difference. The levels of hypersensitive C-reactive protein, lactate dehydrogenase, D-dimer, IL-6, and IL-10 were increased in non-improved patients but declined during treatment in the improved patients. This suggests these mediators are associated with the disease severity and could potentially serve as prognostic markers. Moreover, our data demonstrate that Arbidol is effective in the treatment of COVID-19 patients and may serve as a cost-effective antiviral treatment strategy for patients with moderate to severe COVID-19 symptoms.

SELECTION OF CITATIONS
SEARCH DETAIL